Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Erickson

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|September 17, 2010
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisSrdan Verstovsek, Hagop Kantarjian, Ruben A Mesa, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitorsRobert F Kaltenbach, Mona Patel, Robert E Waltermire, et al.
Antiviral Chemistry & Chemotherapy|July 15, 2003
N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activityJunxing Shi, Judy S Mathew, Phillip M Tharnish, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2002
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variantsRaymond F Schinazi, John Mellors, Holly Bazmi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 5, 2011
Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infectionNiu Shin, Kim Solomon, Naiming Zhou, et al.
Journal of Hematology & Oncology|November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMoshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The Ocular Surface|September 13, 2021
TFOS: Unique challenges and unmet needs for the management of ocular surface diseases throughout the worldSusan Erickson, Amy Gallant Sullivan, Juan Carlos Abad, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|September 17, 2010
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisSrdan Verstovsek, Hagop Kantarjian, Ruben A Mesa, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitorsRobert F Kaltenbach, Mona Patel, Robert E Waltermire, et al.
Antiviral Chemistry & Chemotherapy|July 15, 2003
N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activityJunxing Shi, Judy S Mathew, Phillip M Tharnish, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2002
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variantsRaymond F Schinazi, John Mellors, Holly Bazmi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 5, 2011
Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infectionNiu Shin, Kim Solomon, Naiming Zhou, et al.
Journal of Hematology & Oncology|November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMoshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Haematologica|September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The Ocular Surface|September 13, 2021
TFOS: Unique challenges and unmet needs for the management of ocular surface diseases throughout the worldSusan Erickson, Amy Gallant Sullivan, Juan Carlos Abad, et al.
Pageof 3